{
  "uuid": "",
  "id": "Prostate_Cancer_Risk_Classification.v0.0.1-draft",
  "gdl_version": "2.1",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "name": "Kevin Arjona",
      "email": "kevin.arjona@cambio.se",
      "organisation": "Cambio CDS",
      "date": "2025-07-18"
    },
    "lifecycle_state": "DRAFTED",
    "details": {
      "en": {
        "id": "en",
        "purpose": "To automate the calculation of the prostate cancer risk group to support clinical decision-making.",
        "keywords": [
          "national guidelines",
          "RCC",
          "PSA",
          "ISUP",
          "Gleason score",
          "T-stage",
          "risk",
          "cancer",
          "prostate"
        ],
        "use": " Use in patients with prostate cancer confirmed to be without distant metastases (M0 stage).",
        "misuse": "Not to be used for patients with known metastatic disease (M1), recurrent prostate cancer after primary treatment, or for assessing the risk of other types of cancer. Do not use if any of the mandatory input parameters (T-stage, Gleason, PSA) are unknown.",
        "copyright": "© Cambio CDS"
      }
    },
    "other_details": {
      "references": "Zumsteg ZS, Spratt DE, Pei I, Zhang Z, Yamada Y, Kollmeier M, Zelefsky MJ. A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy. Eur Urol. 2013 Dec;64(6):895-902. doi: 10.1016/j.eururo.2013.03.033. Epub 2013 Mar 23. PMID: 23541457.\n\nGnanapragasam VJ, Bratt O, Muir K, Lee LS, Huang HH, Stattin P, Lophatananon A. The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study. BMC Med. 2018 Feb 28;16(1):31. doi: 10.1186/s12916-018-1019-5. PMID: 29490658; PMCID: PMC5831573.\n\n",
      "en": "Applies the Swedish National Guidelines to classify localized prostate cancer into Very low, Low, Favorable Intermediate, Unfavorable Intermediate, High, or Very High risk groups based on recorded clinical parameters."
    }
  },
  "definition": {
    "data_bindings": {
      "gt0002": {
        "id": "gt0002",
        "model_id": "openEHR-EHR-OBSERVATION.risk_group_classification_for_prostate_cancer_without_known_spread.v0",
        "template_id": "openEHR-EHR-OBSERVATION.risk_group_classification_for_prostate_cancer_without_known_spread.v0",
        "type": "INPUT",
        "elements": {
          "gt0003": {
            "id": "gt0003",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0006]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0008|T1-T2a|",
              "local::at0009|T2b/T2c|",
              "local::at0010|T3a|",
              "local::at0011|T3b/T4|",
              "local::at0035|T1c|"
            ]
          },
          "gt0004": {
            "id": "gt0004",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0039]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0040|Yes|",
              "local::at0041|No|"
            ]
          },
          "gt0005": {
            "id": "gt0005",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0012]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0013|6 (ISUP 1)|",
              "local::at0014|7 (3+4) (ISUP 2)|",
              "local::at0015|7 (4+3) (ISUP 3)|",
              "local::at0016|8 (ISUP 4)|",
              "local::at0017|9-10 (ISUP 5)|"
            ]
          },
          "gt0006": {
            "id": "gt0006",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0036]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0037|Yes|",
              "local::at0038|No|"
            ]
          },
          "gt0007": {
            "id": "gt0007",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0021]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0024|Yes|",
              "local::at0025|No|"
            ]
          },
          "gt0008": {
            "id": "gt0008",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0042]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0043|< 10 µg/l|",
              "local::at0044|10–19 µg/l|",
              "local::at0045|20–39 µg/l|",
              "local::at0046|≥ 40 µg/l|"
            ]
          },
          "gt0009": {
            "id": "gt0009",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0032]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0033|Yes|",
              "local::at0034|No|"
            ]
          }
        }
      },
      "gt0010": {
        "id": "gt0010",
        "model_id": "openEHR-EHR-OBSERVATION.risk_group_classification_for_prostate_cancer_without_known_spread.v0",
        "template_id": "openEHR-EHR-OBSERVATION.risk_group_classification_for_prostate_cancer_without_known_spread.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0011": {
            "id": "gt0011",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0023]",
            "data_type": "DV_CODED_TEXT",
            "allowed_values": [
              "local::at0026|Very low risk|",
              "local::at0027|Low risk|",
              "local::at0028|Favorable intermediate risk|",
              "local::at0029|Unfavorable intermediate risk|",
              "local::at0030|High risk|",
              "local::at0031|Very high risk|"
            ]
          }
        }
      }
    },
    "rules": {
      "gt0012": {
        "id": "gt0012",
        "priority": 3,
        "when": [
          "$gt0003|T-stage|==local::at0035|T1c|",
          "$gt0006|Histological findings ≤ 8 mm cancer in total in 1–4 of 8–12 systematic biopsy cores|==local::at0037|Yes|",
          "$gt0008|PSA|==local::at0043|< 10 µg/l|",
          "$gt0009|PSA density < 0.15 ug/l/cm3|==local::at0033|Yes|"
        ],
        "then": [
          "$gt0011|Risk group classification|=local::at0026|Very low risk|"
        ]
      },
      "gt0013": {
        "id": "gt0013",
        "priority": 2,
        "when": [
          "$gt0003|T-stage|==local::at0008|T1-T2a|"
        ],
        "then": [
          "$gt0011|Risk group classification|=local::at0027|Low risk|"
        ]
      },
      "gt0014": {
        "id": "gt0014",
        "priority": 1,
        "when": [
          "$gt0003|T-stage|==local::at0009|T2b/T2c|"
        ],
        "then": [
          "$gt0011|Risk group classification|=local::at0028|Favorable intermediate risk|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "Prostate Cancer Risk Group Classification",
            "description": "Applies the Swedish National Guidelines to classify localized prostate cancer into risk groups based on recorded clinical parameters."
          },
          "gt0002": {
            "id": "gt0002",
            "text": "openEHR-EHR-OBSERVATION.risk_group_classification_for_prostate_cancer_without_known_spread.v0"
          },
          "gt0003": {
            "id": "gt0003",
            "text": "T-stage"
          },
          "gt0004": {
            "id": "gt0004",
            "text": "Strong suspicion of extraprostatic growth on MRI (EPE/SVI 5)"
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Gleason score"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "Histological findings ≤ 8 mm cancer in total in 1–4 of 8–12 systematic biopsy cores"
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Gleason score consistent in more than half of biopsy specimens"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "PSA"
          },
          "gt0009": {
            "id": "gt0009",
            "text": "PSA density < 0.15 ug/l/cm3"
          },
          "gt0010": {
            "id": "gt0010",
            "text": "openEHR-EHR-OBSERVATION.risk_group_classification_for_prostate_cancer_without_known_spread.v0"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "Risk group classification"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Very low risk",
            "description": ""
          },
          "gt0013": {
            "id": "gt0013",
            "text": "Low Risk",
            "description": ""
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Favorable intermediate risk",
            "description": ""
          }
        }
      }
    }
  }
}